EUVIMEDEUVIMED entdecken
Open Access

Patient experiences with prenatal cell‐free DNA screening in a safety net setting

Kirsten A Riggan iD, Amelia Barwise, Jane Q Yap, Niamh Condon, Megan A Allyse iD

Prenatal Diagnosis · 2024

DOI: 10.1002/pd.6541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Prenatal Diagnosis, 2024. Verfasst von Kirsten A Riggan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Ethics Research Program, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Noninvasive Prenatal Testing, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHGRI NIH HHS, National Human Genome Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Thirty‐five states, including Florida, now cover cell‐free DNA (cfDNA) screening of fetuses for all pregnant patients enrolled in state public insurance programs. We interviewed Black and Hispanic obstetric patients at a safety net clinic in Florida shortly after the state rolled out cfDNA as a first‐tier screening method for publicly insured patients.

Methods

Black and Hispanic patients receiving prenatal care from a prenatal or maternal fetal medicine clinic at a federally qualified health center in Jacksonville, FL were invited to participate in a qualitative interview in English or Spanish to explore experiences and perceptions of prenatal cfDNA screening. Participants were recruited following their first prenatal visit when cfDNA is typically introduced. Interview transcripts were qualitatively analyzed for iterative themes based on principles of grounded theory.

Results

One hundred Black and Hispanic patients ( n = 51 non‐Hispanic Black, n = 43 Hispanic, n = 3 Hispanic Black, n = 3 Not Reported/Other) completed an interview. Participants described minimal opportunity for pre‐screening counseling and limited health literacy about cfDNA or its uses. Some believed that cfDNA could positively impact pregnancy health. Many were unsure if they had received cfDNA even though they were aware of the information provided by it. Most participants expressed an interest in cfDNA as a means for early detection of fetal sex and as an additional indication of general fetal health.

Conclusions

Patient experiences indicate limited informed consent and decision‐making for cfDNA, discordant with professional guidelines on pre‐screen counseling. Our findings suggest that there should be additional investment in implementing cfDNA in safety net settings to ensure that patients and providers receive the support necessary for effective patient counseling and follow‐on care for the ethical implementation of cfDNA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Noninvasive Prenatal TestingCell-Free Nucleic AcidsPregnancyFemaleHumansPrenatal DiagnosisPrenatal CarePatient Outcome Assessment

Substanzen

Cell-Free Nucleic Acids

Autor:innen und Institutionen

  • Biomedical Ethics Research Program, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Maternal-Fetal Medicine, University of Florida Health, Jacksonville, Florida, USA.
  • Department of Obstetrics & Gynecology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Kirsten A Riggan, Megan A Allyse

Förderung

  • NHGRI NIH HHS
  • National Human Genome Research Institute

Zitieren

APA

Riggan, K. A., Barwise, A., Yap, J. Q., Condon, N., & Allyse, M. A. (2024). Patient experiences with prenatal cell‐free DNA screening in a safety net setting. Prenatal Diagnosis. https://doi.org/10.1002/pd.6541

Vancouver

Riggan KA, Barwise A, Yap JQ, Condon N, Allyse MA. Patient experiences with prenatal cell‐free DNA screening in a safety net setting. Prenatal Diagnosis. 2024. doi:10.1002/pd.6541

BibTeX
@article{Riggan2024,
  author = {Riggan, Kirsten A and Barwise, Amelia and Yap, Jane Q and Condon, Niamh and Allyse, Megan A},
  title = {Patient experiences with prenatal cell‐free DNA screening in a safety net setting},
  journal = {Prenatal Diagnosis},
  year = {2024},
  doi = {10.1002/pd.6541}
}
Kostenlos starten →